Pharmacokinetic Interaction and the Safety of Inhaled CHF5259 and CHF6001

Copd Clinical Trial

Official title:

Open Label, Randomized, Repeated-dose, 3-way Crossover Study to Investigate Pharmacokinetic Interaction and the Safety of Inhaled CHF5259 and CHF6001 Administered in Healthy Subjects Via NEXThaler® Dry Powder Inhaler

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03004495
• Other study ID #: CCD-06302AA1-02
• Status: Completed
• Phase: Phase 1
• First received: October 28, 2016
• Last updated: December 22, 2016
• Start date: January 2016
• Est. completion date: August 2016

Study information

• Verified date: December 2016
• Source: Chiesi Farmaceutici S.p.A.
• Contact: n/a
• Is FDA regulated: No
• Health authority: United Kingdom: Medicines and Healthcare Products Regulatory Agency
• Study type: Interventional

Clinical Trial Summary

To evaluate systemic pharmacokinetics of CHF6001 following concomitant administration of CHF6001 and CHF5259, in comparison with the single components, administered in healthy subjects via a multi-dose reservoir NEXThaler® DPI.

Description:

This is randomised open label, 3-way cross-over study. Each 14-day treatment period is separated from the following one by a 21-day wash-out period. Subjects will reside at the clinic facilities during the 14 days treatment period.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 36
• Est. completion date: August 2016
• Est. primary completion date: August 2016
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Both
• Age group: 18 Years to 55 Years

Eligibility

Inclusion Criteria:

• Subject's written informed consent obtained prior to any study-related procedure; Healthy males and females volunteers aged 18-55 years inclusive;

• Ability to understand the study procedures and the involved risks, ability to be trained to use the device correctly

• Non smokers or ex-smokers are eligible.

• Good physical and mental status, determined on the basis of the medical history and a general clinical examination;

• Vital signs checked at screening visit and Day -1: Subjects aged 18-45years:

Diastolic BP 40-90, Systolic BP 90-140; Subjects aged 46-55 years: Diastolic BP 40-90, Systolic BP 90-150

• 12-lead digitised Electrocardiogram (12-lead ECG) considered as normal (40=Heart rate=110bpm,120 ms = PR = 210 ms, QRS = 120 ms, QTcF = 450 ms for males and = 470ms for females) checked at screening;

• Lung function measurements within normal limits: FEV1 > 80% of predicted normal value (according to the Global Lung Function Initiative, ERS Task Force Lung Function Reference Values (1,2) ) and FEV1/FVC ratio > 0.70;

• Male subjects: they and/or their partner of childbearing potential must be willing to use a double contraceptive methods;

• Female subject of non-childbearing potential (WONCBP) Female subjects of childbearing potential (WOCBP) fulfilling one of the following criteria: WOCBP with fertile male partners: they and/or their partner of childbearing potential must be willing to use a double contraceptive methods including one highly effective birth control method and one acceptable birth control method, from the signature of the informed consent and until three months following the last study drug intake; WOCBP with non-fertile male partners: contraception is not required in this case.

Exclusion Criteria:

• Pregnant or lactating women:

• Blood donation (equal or more than 450 ml) or blood loss less than 12 weeks before inhalation of the study medication;

• Positive HIV1 or HIV2 serology; Positive results from the Hepatitis serology which indicates acute or chronic Hepatitis B or Hepatitis C (positive HB surface antigen (HBsAg),HB core antibody ( anti HBc), HC antibody);

• History of substance abuse or drug abuse within 12 months prior to screening visit;

• Clinically significant abnormal 24-h Holter ECG at screening as defined in the Holter interpretative guidelines (Appendix V);

• Any clinically relevant abnormal laboratory value at screening suggesting an unknown disease and requiring further clinical investigation or which may impact the safety of the subject or the evaluation of the result of the study according to the Investigator's judgment;

• Clinically significant and uncontrolled respiratory, cardiac, hepatic, renal, gastrointestinal, endocrine, metabolic, neurologic, respiratory or psychiatric disorder that may interfere with successful completion of this protocol;

• Subjects with medical diagnosis asthma including childhood asthma;

• Subjects known to have intolerance/ hypersensitivity to M3 Antagonists, or any of the excipients contained in any of the formulations used in the trial;

• Any drug treatment, including prescribed or OTC medicines as well as vitamins, homeopathic remedies etc, taken in the 14 days (3 months for any biologic drugs, enzyme-inducing or enzyme-inhibiting drugs e.g., glucocorticoids, phenobarbital, isoniazid) before the screening visit, with the exception of occasional paracetamol (maximum 2 g per day with a maximum of 10 g per 14 days for mild non-excluding conditions), hormonal contraceptives and hormonal replacement treatment for post-menopausal women;

• Treatment within the previous 3 months before the screening visit with any drug known to have a well defined potential for hepatotoxicity (e.g. isoniazide, nimesulide, ketoconazole);

Study Design

Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Copd

Intervention

Drug:
• CHF5259 and CHF6001
b.i.d. for 14 days
• CHF5259 + placebo
b.i.d. for 14 days
• CHF6001 + placebo
b.i.d. for 14 days

Other:
• Placebo
b.i.d. for 14 days

Locations

Country	Name	City	State
United Kingdom	Quintiles CPU	London	UK

Sponsors (2)

Lead Sponsor	Collaborator
Chiesi Farmaceutici S.p.A.	Quintiles, Inc.

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Plasma CHF 5259 and CHF 6001 AUC 0-12,ss (area under the plasma concentration-time curve from time 0 to 12h post dose at steady on Day 14)	To evaluate the pharmacokinetic interaction between CHF 5259 and CHF 6001	On Day 1 and Day 14 at pre-dose, within 15 minutes from dosing and at the following time points, 5, 10, 15, 30, 45 min and 1, 1.5, 2, 3, 4, 6, 8, 12 h post morning dose. At Day 8, Day 12 and Day 13 at pre-dose	No
Primary	Plasma CHF 5259 and CHF 6001 Cmax,ss (maximum plasma concentration at steady state on Day 14)	To evaluate the pharmacokinetic interaction between CHF 5259 and CHF 6001	On Day 1 and Day 14 at pre-dose, within 15 minutes from dosing and at the following time points, 5, 10, 15, 30, 45 min and 1, 1.5, 2, 3, 4, 6, 8, 12 h post morning dose. At Day 8, Day 12 and Day 13 at pre-dose	No
Secondary	Plasma CHF 5259 and CHF 6001 and its metabolites (CHF 5956, CHF 6095) AUC0-12h, Cmax, tmax		On Day 1, Day 14 at the following time points: pre-dose, 5, 10, 15, 30, 45 min and 1, 1.5, 2, 3, 4, 6, 8, 12 h post-morning dose.	No
Secondary	Holter extracted ECG parameters		On Day 1, Day 14 at the following time points: pre-dose, 5, 10, 15, 30, 45 min and 1, 1.5, 2, 3, 4, 6, 8, 12 h post-morning dose.	No
Secondary	Lung function		On Day 1, Day 14: at pre-dose, 5, 15, 30, 45 min and 1, 2 hours post-morning dose	No
Secondary	Vital signs		On Day 1, Day 8 and on Day 14 at the following time points: pre-dose, 15 min, 30 min, 1, 2, 4, 8, 12 h post morning dose. From Day 2 to Day 13 at pre-morning dose only, On Day 15 (24 h after last dose), Day 16 (48 h after last dose) and at follow-up. (BP	No
Secondary	Plasma CHF 5259 and CHF 6001 and its metabolites (CHF 5956, CHF 6095) Cmax		On Day 1, Day 14 at the following time points: pre-dose, 5, 10, 15, 30, 45 min and 1, 1.5, 2, 3, 4, 6, 8, 12 h post-morning dose.	No
Secondary	Plasma CHF 5259 and CHF 6001 and its metabolites (CHF 5956, CHF 6095) tmax		On Day 1, Day 14 at the following time points: pre-dose, 5, 10, 15, 30, 45 min and 1, 1.5, 2, 3, 4, 6, 8, 12 h post-morning dose.	No